Inventor · disambiguated record
Eric M. Ostertag
Also filed as: OSTERTAG ERIC · OSTERTAG ERIC M · OSTERTAG ERIC MICHAEL
32 granted patents·38 pending applications·214 citations·filing 2002–2024
96Inventor score
Files withPOSEIDA THERAPEUTICS INC40OSTERTAG ERIC M9TRANSPOSAGEN BIOPHARMACEUTICALS INC6HERA TESTING LABORATORIES INC4KWIATKOWSKI STEFAN2
Top patents by PatentIndex Score
70 records- 0196US10513686B2Modified stem cell memory T cells, methods of making and methods of using samePOSEIDA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·12 cites·30 claims
- 0295US10329543B2Modified stem cell memory T cells, methods of making and methods of using samePOSEIDA THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·14 cites·28 claims
- 0395US10131885B2Hyperactive piggybac transposasesPOSEIDA THERAPEUTICS INC·Filed 2017·Granted Nov 20, 2018·11 cites·17 claims
- 0494US10287559B2Hyperactive PiggyBac transposasesPOSEIDA THERAPEUTICS INC·Filed 2016·Granted May 14, 2019·7 cites·17 claims
- 0594US8399643B2Nucleic acids encoding hyperactive PiggyBac transposasesOSTERTAG ERIC·Filed 2010·Granted Mar 19, 2013·60 cites·13 claims
- 0693US11718656B2Inducible caspases and methods for usePOSEIDA THERAPEUTICS INC·Filed 2022·Granted Aug 8, 2023·1 cites·10 claims
- 0792US10415024B2Site-specific enzymes and methods of usePOSEIDA THERAPEUTICS INC·Filed 2013·Granted Sep 17, 2019·25 cites·8 claims
- 0892US9546382B2Hyperactive piggybac transposasesPOSEIDA THERAPEUTICS INC·Filed 2013·Granted Jan 17, 2017·12 cites·24 claims
- 0990US8558055B2Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory diseaseOSTERTAG ERIC M·Filed 2010·Granted Oct 15, 2013·16 cites·47 claims
- 1089US10415016B2Modified stem cell memory T cells, methods of making and methods of using samePOSEIDA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·3 cites·22 claims
- 1189US8808748B2Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the sameGHOROGHCHIAN P PETER·Filed 2011·Granted Aug 19, 2014·20 cites·30 claims
- 1286US12358966B2Inducible caspases and methods for usePOSEIDA THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·7 claims
- 1386US11802269B2Superpiggybac transposase compositionsPOSEIDA THERAPEUTICS INC·Filed 2019·Granted Oct 31, 2023·1 cites·5 claims
- 1486US11377480B2Inducible caspases and methods for usePOSEIDA THERAPEUTICS INC·Filed 2017·Granted Jul 5, 2022·2 cites·1 claims
- 1586US8722964B2Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genesOSTERTAG ERIC M·Filed 2010·Granted May 13, 2014·11 cites·34 claims
- 1685US9314005B2Genetically modified rat models for severe combined immunodeficiency (SCID)OSTERTAG ERIC M·Filed 2010·Granted Apr 19, 2016·7 cites·5 claims
- 1784US11089765B2Genetically modified rat models for severe combined immunodeficiency (SCID)HERA TESTING LABORATORIES INC·Filed 2017·Granted Aug 17, 2021·2 cites·12 claims
- 1884US2024156069A1Genetically modified rat models for severe combined immunodeficiency (scid)HERA TESTING LABORATORIES INC·Filed 2023·Application pending·0 cites
- 1981US11485959B2Hyperactive piggybac transposasesPOSEIDA THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·1 cites·16 claims
- 2080US12415844B2BCMA specific VCAR compositions and methods for usePOSEIDA THERAPEUTICS INC·Filed 2018·Granted Sep 16, 2025·1 cites·79 claims
- 2178US10844361B2Site-specific enzymes and methods of usePOSEIDA THERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·1 cites·17 claims
- 2278US2024150734A1Hyperactive piggybac transposasesPOSEIDA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2377US11849709B2Genetically modified rat models for severe combined immunodeficiency (SCID)HERA TESTING LABORATORIES INC·Filed 2021·Granted Dec 26, 2023·0 cites·21 claims
- 2477US10131634B2Method of treating painPOSEIDA THERAPEUTICS INC·Filed 2014·Granted Nov 20, 2018·1 cites·2 claims
- 2577US9533027B2Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the sameVINDICO NANOBIO TECH INC·Filed 2014·Granted Jan 3, 2017·3 cites·10 claims
- 2677US9421247B2Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the sameVINDICO NANOBIO TECH INC·Filed 2014·Granted Aug 23, 2016·3 cites·28 claims
- 2776US2024318136A1Modified stem cell memory t cells, methods of making and methods of using samePOSEIDA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2875US12274247B2Genetically modified rat models for severe combined immunodeficiency (SCID)HERA TESTING LABORATORIES INC·Filed 2021·Granted Apr 15, 2025·0 cites·17 claims
- 2974US2024084251A1Modified stem cell memory t cells, methods of making and methods of using samePOSEIDA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3071US2024226153A9Compositions and methods for selective elimination and replacement of hematopoietic stem cellsPOSEIDA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3163US2021062170A1Site-specific enzymes and methods of usePOSEIDA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3263US2023257737A1Compositions and methods for directing proteins to specific loci in the genomePOSEIDA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3363US2019119636A1Modified stem cell memory t cells, methods of making and methods of using samePOSEIDA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3462US11744861B2Compositions and methods for selective elimination and replacement of hematopoietic stem cellsPOSEIDA THERAPEUTICS INC·Filed 2018·Granted Sep 5, 2023·0 cites·19 claims
- 3560US2016302397A1Genetically modified rat models for severe combined immunodeficiency (scid)TRANSPOSAGEN BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3656US2019135759A1Method of treating painPOSEIDA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3756US2015052624A1Genetically modified rat models for painTRANSPOSAGEN BIOPHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3855US2022042038A1Nanotransposon compositions and methods of usePOSEIDA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3955US2019233843A1Transposon system and methods of usePOSEIDA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4055US2016174533A1Genetically modified rat models for drug metabolismTRANSPOSAGEN BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4154US2017105929A1Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the sameVINDICO NANOBIOTECHNOLOGY LLC·Filed 2016·Application pending·0 cites
- 4254US2023079955A1Anti-muc1 compositions and methods of usePOSEIDA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4353US2016174534A1Genetically modified rat models for pharmacokineticsTRANSPOSAGEN BIOPHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4453US2022372105A1Allogeneic cell compositions and methods of usePOSEIDA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4553US2016174532A1Genetically modified rat models for painTRANSPOSAGEN BIOPHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4651US12385061B2Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expressionPOSEIDA THERAPEUTICS INC·Filed 2018·Granted Aug 12, 2025·0 cites·14 claims
- 4751US11473082B2Compositions and methods for directing proteins to specific loci in the genomePOSEIDA THERAPEUTICS INC·Filed 2016·Granted Oct 18, 2022·0 cites·28 claims
- 4851US2020063157A9Transposon system and methods of usePOSEIDA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4951US2022389077A1Allogeneic cell compositions and methods of usePOSEIDA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5050US2011145936A1Genetically Modified Rat Models for PharmacokineticsOSTERTAG ERIC M·Filed 2010·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →